Cas No. 99854-89-4, 3-(benzylamino)oxolan-2-one

Delgocitinib, a novel Janus kinase inhibitor, holds immense potential in the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. Our meticulously crafted intermediates ensure a streamlined manufacturing process, guaranteeing the timely production and availability of this transformative drug. Collaborate with us to revolutionize the management of inflammatory diseases, providing patients with an effective and life-changing therapy. Together, let's pave the way for a brighter future in inflammatory disease treatment with Delgocitinib.